Expression and Clinical Implications of β-tropomyosin in Myocardial Tissues Across Cardiomyopathies

doi:10.12114/j.issn.1007-9572.2025.0182

Abstract

Abstract:

Background

β-tropomyosin (TPM2) is a key structural protein that regulates muscle contraction, and its abnormal expression is closely associated with the development of various diseases. However, the expression patterns of TPM2 in different types of cardiomyopathies remain unclear.

Objective

To investigate the expression patterns and clinical relevance of TPM2 in myocardial tissues from patients with hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and coronary artery disease (CAD).

Methods

Myocardial tissue samples were collected from patients who underwent heart transplantation or septal myectomy at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology between January 2016 and June 2021, including HCM (septal tissues, n=13), DCM (left ventricular tissues, n=48), and CAD (peri-infarct and non-infarct regions of the left ventricular, n=8). Eight donor hearts (left ventricular tissues, n=8, and septal tissues, n=6) were included as controls. A tissue microarray containing 77 samples was constructed. TPM2 protein expression was assessed by immunohistochemistry and its clinical relevance was analyzed.

Results

Compared to the donor group, TPM2 expression was significantly reduced in the septal tissue of HCM patients (P<0.05). In the HCM group, TPM2 expression in septal tissue was positively correlated with left ventricular end-diastolic volume (r=0.478, P=0.018) and left ventricular lateral wall thickness (r=0.475, P=0.040). TPM2 expression was also significantly reduced in the left ventricular tissue of DCM patients compared to the donor group (P<0.05). In the CAD group, TPM2 expression levels in both peri-infarct and non-infarct regions showed no significant difference compared to controls (P>0.05).

Conclusion

TPM2 exhibits heterogeneous expression patterns across different cardiomyopathies. In HCM patients, downregulation of TPM2 in septal tissue is significantly associated with ventricular remodeling, suggesting that TPM2 may play a critical role in the pathogenesis of HCM and may serve as a potential therapeutic target.

Key words: Dilated cardiomyopathy, Hypertrophic cardiomyopathy, Coronary artery disease, Tropomyosin 2

摘要：

背景

β-原肌球蛋白（TPM2）是调控肌肉收缩的关键结构蛋白，其表达异常与多种疾病的发生密切相关。然而，TPM2在不同类型心肌病中的表达特征尚不明确。

目的

探讨TPM2在肥厚型心肌病（HCM）、扩张型心肌病（DCM）及冠心病（CAD）患者心肌组织中的表达特征及其临床意义。

方法

选取2016年1月—2021年6月于华中科技大学同济医学院附属同济医院接受心脏移植或室间隔部分切除术的HCM（室间隔组织，n=13）、DCM（左心室组织，n=48）、CAD（左心室梗死周边区及非梗死区组织，n=8）患者，并选取8例供体心脏（左心室8例、室间隔6例）作为对照。构建包含77例样本的组织芯片，采用免疫组化法检测TPM2蛋白表达水平，结合临床资料进行相关性分析。

结果

与供体相比，HCM室间隔组织TPM2表达降低（P<0.05）。HCM室间隔组织TPM2表达水平与左心室舒张末期容积（r=0.478，P=0.018）及左心室侧壁厚度（r=0.475，P=0.040）呈正相关。与供体相比，DCM左心室组织TPM2表达降低（P<0.05）。CAD梗死周边区和非梗死区TPM2表达水平分别与供体比较，差异无统计学意义（P>0.05）。

结论

TPM2在不同心肌病中的表达呈现异质性，其中HCM患者室间隔组织TPM2表达下调与心室重构显著相关，提示其在HCM病理进程中可能发挥重要作用，或为潜在治疗靶点。

关键词: 扩张型心肌病, 肥厚型心肌病, 冠心病, β-原肌球蛋白

WANG Xuesheng,ZHANG Yusong,GONG Fuhan, et al. Expression and Clinical Implications of β-tropomyosin in Myocardial Tissues Across Cardiomyopathies[J]. Chinese General Practice, 2026, 29(03): 311-315. DOI: 10.12114/j.issn.1007-9572.2025.0182.
王学胜,张羽松,龚福汉等. β-原肌球蛋白在不同心肌病患者心肌组织中的表达及临床价值研究[J]. 中国全科医学, 2026, 29(03): 311-315. DOI: 10.12114/j.issn.1007-9572.2025.0182.

Figures/Tables 3

References 13

[1]	刘明波，何新叶，杨晓红，等. 《中国心血管健康与疾病报告2023》要点解读[J]. 中国心血管病研究, 2025, 28(1): 20-38. DOI: 10.12114/j.issn.1007-9572.2024.0293.
[2]	NAKAMURA M, SADOSHIMA J. Mechanisms of physiological and pathological cardiac hypertrophy[J]. Nat Rev Cardiol, 2018, 15(7): 387-407. DOI: 10.1038/s41569-018-0007-y.
[3]	CLARKSON E, COSTA C F, MACHESKY L M. Congenital myopathies: diseases of the actin cytoskeleton[J]. J Pathol, 2004, 204(4): 407-417. DOI: 10.1002/path.1648.
[4]	ZHANG H, CHANG M Y, CHEN D Y, et al. Congenital myopathies: pathophysiological mechanisms and promising therapies[J]. J Transl Med, 2024, 22(1): 815. DOI: 10.1186/s12967-024-05626-5.
[5]	MCADOW J, YANG S, OU T, et al. A pathogenic mechanism associated with myopathies and structural birth defects involves TPM2-directed myogenesis[J]. JCI Insight, 2022, 7(12): e152466. DOI: 10.1172/jci.insight.152466.
[6]	MARSTON S, MEMO M, MESSER A, et al. Mutations in repeating structural motifs of tropomyosin cause gain of function in skeletal muscle myopathy patients[J]. Hum Mol Genet, 2013, 22(24): 4978-4987. DOI: 10.1093/hmg/DDT345.
[7]	CLARKE N F, DOMAZETOVSKA A, WADDELL L, et al. Cap disease due to mutation of the beta-tropomyosin gene(TPM2)[J]. Neuromuscul Disord, 2009, 19(5): 348-351. DOI: 10.1016/j.nmd.2009.03.003.
[8]	MOKBEL N, ILKOVSKI B, KREISSL M, et al. K7del is a common TPM2 gene mutation associated with nemaline myopathy and raised myofibre calcium sensitivity[J]. Brain, 2013, 136(Pt 2): 494-507. DOI: 10.1093/brain/aws348.
[9]	KEE A J, HARDEMAN E C. Tropomyosins in skeletal muscle diseases[J]. Adv Exp Med Biol, 2008, 644: 143-157. DOI: 10.1007/978-0-387-85766-4_12.
[10]	MARTTILA M, LEHTOKARI V L, MARSTON S, et al. Mutation update and genotype-phenotype correlations of novel and previously described mutations in TPM2 and TPM3 causing congenital myopathies[J]. Hum Mutat, 2014, 35(7): 779-790. DOI: 10.1002/humu.22554.
[11]	OCHALA J, GOKHIN D S, PÉNISSON-BESNIER I, et al. Congenital myopathy-causing tropomyosin mutations induce thin filament dysfunction via distinct physiological mechanisms[J]. Hum Mol Genet, 2012, 21(20): 4473-4485. DOI: 10.1093/hmg/dds289.
[12]	ROBINSON P, LIPSCOMB S, PRESTON L C, et al. Mutations in fast skeletal troponin I, troponin T, and beta-tropomyosin that cause distal arthrogryposis all increase contractile function[J]. FASEB J, 2007, 21(3): 896-905. DOI: 10.1096/fj.06-6899com.
[13]	NAIMI B, HARRISON A, CUMMINS M, et al. A tropomyosin-2 mutation suppresses a troponin I myopathy in Drosophila[J]. Mol Biol Cell, 2001, 12(5): 1529-1539. DOI: 10.1091/mbc.12.5.1529.

分类	例数	性别（男/女）	年龄（±s，岁）	BMI （±s，kg/m²）	高血压史[例（%）]	糖尿病史[例（%）]	LVEDV （±s，mL）	LVLWT （±s，mm）	EF （±s，%）
HCM患者	13	9/4	53.1±11.4	23.5±2.0	6（46.2）	2（15.4）	41.25±14.13	9.9±4.2	60.95±13.89
DCM患者	48	40/8	42.0±15.1	21.7±3.8	7（14.6）	7（14.6）	71.51±12.17		25.33±11.66
CAD患者	8	8/0	61.7±6.9	22.9±2.9	3（37.5）	3（37.5）	48.67±25.00		37.00±10.52
F（χ²）值		3.072^a	8.188	1.450	6.765^a	2.552^a	25.181		44.274
P值		0.215	<0.01	0.244	0.034	0.279	<0.01		<0.01

分类	例数	性别（男/女）	年龄（±s，岁）	BMI （±s，kg/m²）	高血压史[例（%）]	糖尿病史[例（%）]	LVEDV （±s，mL）	LVLWT （±s，mm）	EF （±s，%）
HCM患者	13	9/4	53.1±11.4	23.5±2.0	6（46.2）	2（15.4）	41.25±14.13	9.9±4.2	60.95±13.89
DCM患者	48	40/8	42.0±15.1	21.7±3.8	7（14.6）	7（14.6）	71.51±12.17		25.33±11.66
CAD患者	8	8/0	61.7±6.9	22.9±2.9	3（37.5）	3（37.5）	48.67±25.00		37.00±10.52
F（χ²）值		3.072^a	8.188	1.450	6.765^a	2.552^a	25.181		44.274
P值		0.215	<0.01	0.244	0.034	0.279	<0.01		<0.01

[1]	Cardiovascular Internal Medicine Professional Committee of China Medical Education Association, Cardiovascular Health Medicine Branch of China International Exchange and Promotion Association for Medical Care. Expert Consensus on Early Screening and Prevention of Coronary Artery Disease in Young People [J]. Chinese General Practice, 2026, 29(02): 137-147.
[2]	CHAI Yiyi, YE Qingfang, LIN Ping, LI Ling. Current Status and Influencing Factors of Motoric Cognitive Risk in Patients with Coronary Artery Disease in Frigid Zone [J]. Chinese General Practice, 2025, 28(14): 1730-1736.
[3]	WANG Rui, OUYANG Lina, WU Qian, NIU Yuanyuan, LI Guilan, ZHU Li. The Value of CT-FFR in Predicting Major Adverse Cardiovascular Events in Patients with Obstructive Coronary Artery Disease [J]. Chinese General Practice, 2025, 28(06): 713-719.
[4]	ZHANG Qiongdan, MAO Zhuoni, HUANG Dan, FANG Li. Correlation of Nucleolin with the Stability and Severity of Coronary Plaque in Acute Coronary Syndrome [J]. Chinese General Practice, 2024, 27(36): 4561-4567.
[5]	JIA Jia, LIU Jiahui, JI Wenjun, ZHENG Bo, WANG Xingang, FAN Fangfang, LI Yin, ZHANG Long, ZHANG Yan. Analysis of Influencing Factors of Plasma Proprotein Convertase Subtilisin/Kexin Type 9 in Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2024, 27(36): 4568-4574.
[6]	HE Junhui, WAN Daguo, DONG Jing, ZHANG Juan. Correlation Analysis between Pan-immune Inflammatory Value, Systemic Immune-inflammatory Index, and Vulnerable Plaques in Patients with Acute Coronary Syndrome [J]. Chinese General Practice, 2024, 27(24): 2976-2981.
[7]	ZHAO Hui, LI Wenhao, CHENG Gong, CHEN Liang, LIANG Chenyuan, WANG Yiyang, JIANG Hongying, JIANG Ruijia. Analysis of Adverse Reactions in the Assessment of Coronary Microvascular Disease by Adenosine Load and Adenosine Disodium Triphosphate Load [J]. Chinese General Practice, 2024, 27(17): 2109-2112.
[8]	WANG Aolong, ZHU Mingjun. Application Analysis of the Outcome Measures in Randomized Controlled Trials of Traditional Chinese Medicine in the Treatment of Coronary Microvascular Disease [J]. Chinese General Practice, 2024, 27(02): 217-225.
[9]	YANG Ling, DU Xueping, DONG Jianqin, DONG Yuming. Exercise Tolerance and Its Influencing Factors in Patients with Stable Coronary Artery Disease under Standardized Community Management [J]. Chinese General Practice, 2024, 27(01): 51-58.
[10]	WANG Qiushi, LI Hongwei. The Predictive Value of CHA₂DS₂-VASc Score on Major Adverse Cardiovascular Events in Patients with Three Vessels or Left Main Diseases of Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(33): 4130-4136.
[11]	CAI Gaojun, SHI Ganwei, LI Feng, LI Wenhua, YAN Yongmin, XUE Sheliang, XIAO Jianqiang, GU Jun, SONG Yanbin, ZHANG Liuyan, LU Wei, GONG Chun. How to Improve the Success Puncture Rate of Distal Transradial Artery Approach, "Winding Path to the Secluded": Summary of the Experience of More than 2 000 Cases [J]. Chinese General Practice, 2023, 26(27): 3361-3365.
[12]	YUAN Mingpei, LIN Yaowang, BEI Weijie, LIU Huadong, DONG Shaohong, SUN Xin. Feasibility of Retrograde Recanalization of Occluded Radial Artery via Distal Transradial Artery Approach: a Single-center Prospective Study [J]. Chinese General Practice, 2023, 26(27): 3373-3377.
[13]	LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372.
[14]	LAN Yonghao, KE Erqin, HAN Rui, MEI Yingchen, LIU Wei. Percutaneous Coronary Intervention via Distal Transradial Approach: Strengths, Weaknesses, Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(27): 3355-3360.
[15]	GAO Yang, WANG Yunxia, ZHANG You, GAO Chuanyu. Lipid Goal Attainment Rate and Influencing Factors in 45-year-old or Younger Acute Coronary Syndrome Patients with an Ultra-high Risk of Atherosclerotic Cardiovascular Disease after Lipid-lowering Treatment [J]. Chinese General Practice, 2023, 26(27): 3383-3387.